ANTIBIOTIC THERAPY OF INFECTIOUS EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: PATIENTS WITH THE RISK OF POOR RESPONSE TO ANTIBIOTICS


Cite item

Full Text

Abstract

The article discusses the general and particular problems of treatment and prevention of infectious exacerbations of chronic obstructive pulmonary disease (COPD) in terms of optimizing the choice of antibiotic therapy. Applicability of use of respiratory fluoroquinolones, particularly levofloxacin, for the treatment of exacerbations of COPD and chronic bronchitis is validated. It is emphasized that the effectiveness of antibacterial drugs in a patient with infectious exacerbation of COPD, ultimately is defined by prolonged recurrence-free period of the disease. With this context, levofloxacin can be considered as optimal antibacterial drug for the treatment of exacerbations of COPD, because the main goal of antibiotic therapy in these patients - eradication of etiologically significant microorganisms. Prolonged recurrence-free period provides a low demand for antibacterial drugs, reduces the number of doctor visits and hospitalization rate, thereby improves the quality of life and reduces treatment costs.

References

  1. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003;21(41):46-53.
  2. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;151:1418-22.
  3. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
  4. Zielinski J, MacNee W, Wedzicha J, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997;52:43-47.
  5. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106;196-204.
  6. Elmes PC, King TK, Langlands JH, et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. BMJ 1965;2:904-08.
  7. Jorgensen AF, Coolidge J, Pedersen PA, et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis: a double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992;10:7-11.
  8. Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001;358:2020-25.
  9. Pines A, Raafat H, Plucinski K, et al. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. BMJ 1968;2:735-38.
  10. Allegra L,Grassi C, Grossi E, et al. Ruolo degli antidiotici nel trattamento delle riacutizza della bronchite cronica. Ital J Chest Dis 1991;45:138-48.
  11. Saint S, Bent S, Vittinghof E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analisis. JAMA 1995;273:957-60.
  12. Ram F, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3.
  13. Puhan M, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007;8:30.
  14. Blasi F, Ewig S, Torres A, et al. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm Pharmacol Ther 2006;19:361-69.
  15. De Abate CA, Russel M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis. Respir Care 1997;42:206-13.
  16. Shah PM, Maesen FP, Dolmann A, et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999;43:529-39.
  17. Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 2002;24:1414-25.
  18. Habib MP, Russell M, De Abate CA, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in the treatment of acute exacerbations of chronic bronchitis. Infect Dis Clin Practice 1998;7:1-9.
  19. Amsden GW, Baird IM, Simon S, et al. Efficacy and Safety of Azithromycin vs Levofloxacin in the Outpatient Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Chest 2003;123:772-77.
  20. Lode H, Eller J, Linnhoff A, et al. The Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 2004;24:947-53.
  21. Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007;29:1127-37.
  22. Sethi S, Fogarty C, Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 2004;98:697-707.
  23. Urueta-Robledo J, Ariza H, Jardim JR, et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: The Latin American Cohort. Respir Med 2006;100:1504-11.
  24. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II // Клин. микробиол. антимикроб. химиотер 2006. № 8(1). C. 33-47.
  25. Charlene L. Antimicrobial-Resistant Streptococcus pneumoniae Isolated From Patients With Acute Bacterial Exacerbation of Chronic Bronchitis. Тhe 100th International Conference of the American Thoracic Society. Orlando, FL 2004;47:E28.
  26. Peifer G, Veyssier P, Zuck P. Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors. Eur Resp J 2003;22(45):3558.
  27. Pechere J, Hughes D, Kardas P, et al. Non compliance with antibiotic therapy for acute community infections: a global survey. Int J of Antimicrob Agents 2007;29:245-53.
  28. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J of Аntimicrob Сhemother 2007;59(3):531-36.
  29. Miravitlles М. Exacerbations of chronic оbstructive pulmonary disease when are bacteria important? Eur Respir J 2002;20(36):9-19.
  30. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Левофлоксацин и макролиды при обострении хронического бронхита. Результаты длительного мониторинга больных // Инфекции и антимикробная терапия 2005. № 1. C. 20-27.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies